Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals
- PMID: 17941699
- DOI: 10.1021/tx7002195
Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals
Abstract
Combretastatins are stilbene-based, tubulin depolymerization agents with selective activity against the tumor vasculature; two variants (A-1 and A-4) are currently undergoing clinical trials. Combretastatin A-1 (CA1) has a greater antitumor effect than combretastatin A-4 (CA4). We hypothesized that this reflects the enhanced reactivity conferred by the second (ortho) phenolic moiety in CA1. Oxidation of CA1 by peroxidase, tyrosinase, or Fe(III) generates a species with mass characteristics of the corresponding ortho-quinone Q1. After administration of CA1-bis(phosphate) to mice, the hydroquinone-thioether conjugate Q1H2-SG, formed from the nucleophilic addition of GSH to Q1, was detected in liver. In competition, electrocyclic ring closure of Q1, over a few minutes at pH 7.4, leads to a second ortho-quinone product Q2, characterized by exact mass and NMR. This product was also generated by human promyelocytic leukemia (HL-60) cells in vitro, provided that superoxide dismutase was added. Q2 is highly reactive toward glutathione (GSH) and ascorbate, stimulating oxygen consumption in a catalytic manner. Free radical intermediates formed during autoxidation of CA1 were characterized by EPR, and the effects of GSH and ascorbate on the signals were studied. Pulse radiolysis was used to initiate selective one-electron oxidation or reduction and provided further evidence, from the differing absorption spectra of the radicals formed on oxidation of CA1 or reduction of Q2, that two different quinones were formed on oxidation of CA1. The results demonstrate fundamental differences between the pharmacological properties of CA1 and CA4 that provide two possible explanations for their differential activities in vivo: oxidative activation to a quinone intermediate likely to bind to protein thiols and possibly to nucleic acids and stimulation of oxidative stress by enhancing superoxide/hydrogen peroxide production. The observation of the GSH conjugate Q1H2-SG in vivo provides a new marker for oxidative metabolism of relevance to current clinical trials of CA1-bis(phosphate) (OXi4503).
Similar articles
-
Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study.Free Radic Res. 2005 Jun;39(6):649-57. doi: 10.1080/10715760500097906. Free Radic Res. 2005. PMID: 16036343
-
[Free oxygen radiacals and kidney diseases--part I].Med Pregl. 2000 Sep-Oct;53(9-10):463-74. Med Pregl. 2000. PMID: 11320727 Review. Croatian.
-
Metabolic activation of PCBs to quinones: reactivity toward nitrogen and sulfur nucleophiles and influence of superoxide dismutase.Chem Res Toxicol. 1996 Apr-May;9(3):623-9. doi: 10.1021/tx950117e. Chem Res Toxicol. 1996. PMID: 8728508
-
Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase.Cancer Res. 2001 Nov 1;61(21):7777-84. Cancer Res. 2001. PMID: 11691792
-
Reduction of protein radicals by GSH and ascorbate: potential biological significance.Amino Acids. 2010 Nov;39(5):1131-7. doi: 10.1007/s00726-010-0610-7. Epub 2010 Jun 9. Amino Acids. 2010. PMID: 20532951 Review.
Cited by
-
Microtubule Organization Is Essential for Maintaining Cellular Morphology and Function.Oxid Med Cell Longev. 2022 Mar 7;2022:1623181. doi: 10.1155/2022/1623181. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35295719 Free PMC article. Review.
-
Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules.Int J Mol Sci. 2024 Jul 24;25(15):8078. doi: 10.3390/ijms25158078. Int J Mol Sci. 2024. PMID: 39125647 Free PMC article.
-
Anti-angiogenic drugs: direct anti-cancer agents with mitochondrial mechanisms of action.Oncotarget. 2017 Sep 13;8(51):88670-88688. doi: 10.18632/oncotarget.20858. eCollection 2017 Oct 24. Oncotarget. 2017. PMID: 29179466 Free PMC article.
-
Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent.Leukemia. 2012 Aug;26(8):1771-8. doi: 10.1038/leu.2012.48. Epub 2012 Feb 20. Leukemia. 2012. PMID: 22343591 Free PMC article.
-
A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia.Cancers (Basel). 2019 Dec 26;12(1):74. doi: 10.3390/cancers12010074. Cancers (Basel). 2019. PMID: 31888052 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous